| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD6 |
| Clinical data | |
| Trade names | Alzumab |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Itolizumab (INN, trade name Alzumab) is a 'first in class' humanized IgG1 monoclonal antibody developed by Biocon[1] and the Center of Molecular Immunology (CIM), Havana.[2]
- ^ Jayaramun K (December 2013). "Biocon's first-in-class anti-CD6 mAb reaches the market". Nat. Biotechnol. Vol. 31, no. 12. United Kingdom. pp. 1062–3.
- ^ "India prepares to test Itolizumab, the drug credited for lowering Covid mortality in Cuba". May 30, 2020.
